$1.22
-0.02-1.61%
At close: Jul 20, 5:00 PM EST
$1.23
0.01451.19%
After Hours: 8:36 AM EST
Metagenomi Therapeutics Inc Earnings Estimates
MGXNASDAQ
Metagenomi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:MGX
Metagenomi Therapeutics (MGX) is scheduled to report Q2 earnings on August 11, 2026. Analysts estimate EPS of $-0.57 and quarterly revenue of $3.50M.
In the most recent quarter (Q1), Metagenomi Therapeutics reported EPS of $-0.61, missing estimates of $-0.56 by 0.09%. Revenue came in at $1.25M, missing the estimate of $5.52M by 0.77%.
Metagenomi Therapeutics has missed EPS estimates in 2 consecutive quarters.
Over the last 4 quarters, Metagenomi Therapeutics has averaged an EPS surprise of 0.07% and a revenue surprise of 0.36%.
Earnings Date
Aug 11
EPS Estimate
$-0.570
Quarterly Revenue Estimate
$3.50M
Annual Revenue
(as of Mar 31)
(as of Mar 31)
$22.33M
Metagenomi Therapeutics Earnings History
Analyze the earnings history of Metagenomi Therapeutics using advanced sorting and filters.
Loading calendar...
Metagenomi Therapeutics (MGX) Earnings Per Share
The chart below shows Metagenomi Therapeutics's reported EPS compared to analyst estimates over recent quarters.
Metagenomi Therapeutics (MGX) Revenue
The chart below shows Metagenomi Therapeutics's reported revenue compared to analyst estimates over recent quarters.
FAQ
When is Metagenomi Therapeutics (NASDAQ:MGX) reporting earnings?
Metagenomi Therapeutics (MGX) is scheduled to report earnings on August 11, 2026. The last reported earnings were for reported on May 11, 2026 for Q1.
What were the latest earnings per share (EPS) for Metagenomi Therapeutics (NASDAQ:MGX)?
The Actual EPS was $-0.61, which missed the estimate of $-0.56.
What were Metagenomi Therapeutics’s (NASDAQ:MGX) revenues?
The Actual Revenue was $1.25M, which missed the estimate of $5.52M.
